Haematological malignancy Cancer Leukaemia of unspecified cell type
Conditions
Interventions
Infusion with CD4 positive donor lymphocytes vs standard care.
Sponsors
Leiden University Medical Centre (Netherlands)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Both males and females 2. Age from 18 to 70 years 3. Patients with acute myeloid leukaemia (AML), myelodysplasia (MDS), acute lymphocytic leukaemia (ALL), chronic myeloid leukaemia (CML) in accelerated phase or blastic transformation, chronic lymphocytic leukaemia (CLL), multiple myeloma (MM) or aggressive lymphoma, who received an allogeneic stem cell transplantation.
Exclusion criteria
Exclusion criteria: 1. Systemic immunosuppressive treatment 2. Progressive Graft Versus Host Disease (GVHD) 3. GVHD of the skin greater than grade 2 4. Progressive disease needing cytoreductive treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Immune reconstitution at 6 months. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Chimerism and disease status as measured by minimal residual disease at 6 months 2. Incidence of viral infections between 3 and 6 months | — |
Countries
Netherlands
Outcome results
None listed